At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 394 enrolled
Drug / intervention
IBI-10090 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery
In Brief
A Phase 3 clinical trial evaluating IBI-10090 and Placebo for Inflammation and Cataracts. Completed, enrolled 394 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether IBI-10090 injection is effective in the treatment of inflammation associated with cataract surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInflammation, Cataracts
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 2013
Enrollment StartJan 2014
Primary CompletionOct 2014
TodayJul 2026
First PostedDec 10, 2013
Enrollment StartJan 1, 2014
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 12.6 years ago
Interventions
IBI-10090drug
Placebodrug
Placebo